MX9701529A - 1,1,2-triphenylbut-1-ene derivatives for treating alzheimers disease. - Google Patents

1,1,2-triphenylbut-1-ene derivatives for treating alzheimers disease.

Info

Publication number
MX9701529A
MX9701529A MX9701529A MX9701529A MX9701529A MX 9701529 A MX9701529 A MX 9701529A MX 9701529 A MX9701529 A MX 9701529A MX 9701529 A MX9701529 A MX 9701529A MX 9701529 A MX9701529 A MX 9701529A
Authority
MX
Mexico
Prior art keywords
triphenylbut
alzheimers disease
ene derivatives
treating alzheimers
methyl
Prior art date
Application number
MX9701529A
Other languages
Spanish (es)
Other versions
MXPA97001529A (en
Inventor
David Burton Maclean
David Duane Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9701529A publication Critical patent/MX9701529A/en
Publication of MXPA97001529A publication Critical patent/MXPA97001529A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention provides novel methods of inhibiting uterine fibrosis comprising administering to a mammal in need of such treatment an effective amount of a compound of formula 1 (see formula) wherein R1 and R2 may be the same or different provided that, when R1 and R2 are the same, each is a methyl or ethyl group, and, when R1 and R2 are different, one of them is a methyl or ethyl group and the other is hydrogen or a benzyl group; or a pharmaceutically acceptable salt thereof
MXPA/A/1997/001529A 1996-02-28 1997-02-27 Use of (e) -1- [4 '- (2-alkylaminoetoxy) phenyl] -1- (3'-hydroxypenyl) -2-fenilbut-1-enos to inhibit pathologi disorders MXPA97001529A (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US1241196P 1996-02-28 1996-02-28
US1240496P 1996-02-28 1996-02-28
US1240296P 1996-02-28 1996-02-28
US1240396P 1996-02-28 1996-02-28
US1240196P 1996-02-28 1996-02-28
US1241096P 1996-02-28 1996-02-28
US012402 1996-02-28
US012403 1996-02-28
US012401 1996-02-28
US012404 1996-02-28
US012410 1996-02-28
US012411 1996-02-28

Publications (2)

Publication Number Publication Date
MX9701529A true MX9701529A (en) 1998-06-28
MXPA97001529A MXPA97001529A (en) 1998-10-30

Family

ID=

Also Published As

Publication number Publication date
CN1165651A (en) 1997-11-26
EP0792640A2 (en) 1997-09-03
JPH09328421A (en) 1997-12-22
KR970061247A (en) 1997-09-12
IL120268A0 (en) 1997-06-10
EP0792640A3 (en) 1998-07-08
AU707455B2 (en) 1999-07-08
CA2198571A1 (en) 1997-08-28
AU1495697A (en) 1997-09-04

Similar Documents

Publication Publication Date Title
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
FI925342A0 (en) Process for the preparation of therapeutically active (+) - - (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol
MX9803809A (en) Biphenyl hydroxamate inhibitors of matrix metalloproteinases.
MY119375A (en) Treatment of tinnitus using neuroprotective agents
RU94044436A (en) Method of suppression of skin and vagina atrophy
UA41355C2 (en) Agent for treating neuro-aids
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
ZA948031B (en) Methods of inhibiting uterine fibroses
RU94044453A (en) Use of 2-phenyl-3-aroylbenzothiophenes for seborrhea and acne inhibition
ZA967880B (en) Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha
RU94037233A (en) Use of 2-phenyl-3-aroylbenzothiophenes for drug-resistant neoplasma treatment
CA2198580A1 (en) Combination therapy to treat osteoporosis
MX9709466A (en) Methods of inhibiting melanoma.
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
MX9701529A (en) 1,1,2-triphenylbut-1-ene derivatives for treating alzheimers disease.
MX9701333A (en) Methods for inhibiting neuronal damage.
MX9701606A (en) Combination therapy to prevent bone loss- progesterone and strogen.
RU94044457A (en) Use of benzthiophenes for hirsutism and alopecia inhibition
AU4944899A (en) New pharmaceutically active compounds
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
MX9604692A (en) Quinoxaline derivatives for treating tinnitus.
MX9701528A (en) 1,1,2-triphenylbut-1-ene derivatives for treating alzheimers disease.
MX9701532A (en) Method of increasing testosterone.
RU94044487A (en) Use of 2-phenyl-3-aroylbenzothiophenes for male sterility treatment